Australia markets closed

Esperion Therapeutics, Inc. (ESPR)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.7000+0.0500 (+3.03%)
At close: 04:00PM EDT
1.7001 +0.00 (+0.01%)
After hours: 05:34PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 333.58M
Enterprise value 413.41M
Trailing P/E N/A
Forward P/E 1.32
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.89
Price/book (mrq)98.42
Enterprise value/revenue 1.49
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.00
52-week change 326.87%
S&P500 52-week change 322.62%
52-week high 33.4000
52-week low 30.7000
50-day moving average 32.1150
200-day moving average 32.2430

Share statistics

Avg vol (3-month) 36.3M
Avg vol (10-day) 33.05M
Shares outstanding 5196.22M
Implied shares outstanding 6196.22M
Float 8194.83M
% held by insiders 10.50%
% held by institutions 170.52%
Shares short (15 Aug 2024) 441.73M
Short ratio (15 Aug 2024) 48.3
Short % of float (15 Aug 2024) 421.32%
Short % of shares outstanding (15 Aug 2024) 421.27%
Shares short (prior month 15 July 2024) 439.42M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)30 June 2024

Profitability

Profit margin -35.46%
Operating margin (ttm)3.49%

Management effectiveness

Return on assets (ttm)1.05%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)277.79M
Revenue per share (ttm)1.91
Quarterly revenue growth (yoy)186.30%
Gross profit (ttm)N/A
EBITDA 4.99M
Net income avi to common (ttm)-98.5M
Diluted EPS (ttm)-0.8500
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)189.3M
Total cash per share (mrq)0.96
Total debt (mrq)269.14M
Total debt/equity (mrq)N/A
Current ratio (mrq)1.97
Book value per share (mrq)-1.77

Cash flow statement

Operating cash flow (ttm)-9.76M
Levered free cash flow (ttm)6.91M